Indications for IVIG in rheumatic diseases

Rheumatology (United Kingdom)

Volumn 54, Issue 3, 2015, Pages 383-391

  Mulhearn, Ben ^a   Bruce, Ian N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Intravenous immunoglobulin; IVIG; Kawasaki disease; Lupus; Myopathy; Myositis; Review; rheumatic disease; Vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; CORTICOSTEROID; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB;

ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC FATIGUE SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; LUPUS VULGARIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84941646510     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu429     Document Type: Review

References (75)

1. Sewell WAC, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107: 387-93.
2. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(Suppl): S525-53.
3. Department of Health. Clinical Guidelines for Immunoglobulin Use: Second Edition Update. July 2011. http://www.ivig.nhs.uk/documents/dh_129666.pdf (19 March 2013, date last accessed).
4. Burns JC, Shike H, Gordon JB et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996;28:253-7.
5. Furusho K, Sato K, Soeda T et al. High-dose intravenous gammaglobulin for Kawasaki disease [letter]. Lancet 1983; 2:1359.
6. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96: 1057-61.
7. Oates-Whitehead RM, Baumer JH, Haines L et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003;4: CD004000.
8. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
9. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574-96.
10. Arnal C, Piette JC, Léone J et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29: 75-83.
11. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009-15.
12. Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum 2005;35:175-84.
13. Ubogu EE, Zaidat OO, Suarez JI. Acute motor-sensory axonal neuropathy associated with active systemic lupus erythematosus and anticardiolipin antibodies. J Clin Rheumatol 2001;7:326-31.
14. Santiago-Casas Y, Peredo RA, Vilá LM. Efficacy of lowdose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barré syndromelike acute axonal neuropathies: report of two cases. Lupus 2013;22:324-7.
15. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996;34:824-9.
16. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
17. Cherin P, Pelletier S, Teixeira A et al. Results and longterm followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-74.
18. Miyasaka N, Hara M, Koike T et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012;22:382-93.
19. Dalakas MC, Sonies B, Dambrosia J et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6.
20. Walter MC, Lochmüller H, Toepfer M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-8.
21. Enk A. European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009;19:90-8.
22. Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15: 893-908.
23. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991;80:605-12.
24. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993;44:237-42.
25. Anderson D, Ali K, Blanchette V et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007;21(Suppl 1):S9-56.
26. Wondergem MJ, Overbeeke M, Som N et al. Mixed autoimmune haemolysis in a SLE patient due to aspecific and anti-JKA autoantibodies; case report and review of the literature. Haematologica 2006;91(Suppl):ECR12.
27. Gomard-Mennesson E, Ruivard M, Koenig M et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006;15:223-31.
28. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003;142:678-83.
29. Llanos C, Izmirly PM, Katholi M et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009;60: 3091-7.
30. Friedman DM, Llanos C, Izmirly PM et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010;62:1138-46.
31. Pisoni CN, Brucato A, Ruffatti A et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2011;62:1147-52.
32. Routsias JG, Kyriakidis NC, Friedman DM et al. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum 2011;63:2783-9.
33. Lim KS, Cheong KL, Tan CT. Periodic lateralized epileptiform discharges in neuropsychiatric lupus: association with cerebritis in magnetic resonance imaging and resolution after intravenous immunoglobulin. Lupus 2010;19: 748-52.
34. Espírito Santo J, Gomes MF, Gomes MJ et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol 2010;38:307-18.
35. Bianchi MT, Lavigne C, Sorond F, Bermas B. Transient life-threatening cerebral edema in a patient with systemic lupus erythematosus. J Clin Rheumatol 2009;15:181-4.
36. Meissner M, Sherer Y, Levy Y et al. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19:199-201.
37. So MW, Koo BS, Kim YJ et al. Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus. Mod Rheumatol 2014;24: 855-7.
38. Perricone R, De Carolis C, Kröegler B et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology 2008;47:646-51.
39. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354: 569-70.
40. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
41. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
42. Francioni C, Galeazzi M, Fioravanti A et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-8.
43. Schroeder JO, Zeuner RA, Euler HH, Löffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
44. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999;8:705-12.
45. Hundt M, Manger K, Dörner T et al. Treatment of acute exacerbation of systemic lupus erythematosus with highdose intravenous immunoglobulin. Rheumatology 2000; 39:1301-2.
46. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol 2012;42: 247-55.
47. Sherer Y, Kuechler S, Jose Scali J et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008;10:55-7.
48. Bucciarelli S, Espinosa G, Cervera R et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006;54:2568-76.
49. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003;12: 524-9.
50. Silverman ED, Cawkwell GD, Lovell DJ et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994;21:2353-8.
51. Lapraik C, Watts R, Bacon P et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007;46:1615-6.
52. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
53. Nencini P, BaruffiMC, Abbate R et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189-93.
54. Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus 2004;13:478-80.
55. Keeling D, Mackie I, Moore GW et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
56. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
57. De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
58. Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
59. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
60. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
61. Lovell DJ, Ruperto N, Goodman S et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
62. GroothoffJW, van Leeuwen EF. High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br Med J (Clin Res Ed) 1988;296:1362-3.
63. Uziel Y, Laxer RM, Schneider R, Silverman ED. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol 1996;23:910-8.
64. Beukelman T, Patkar NM, Saag KG et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63: 465-82.
65. Clowse ME, Copland SC, Hsieh TC et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 2011;63:1777-81.
66. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
67. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9.
68. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993;336:469-72.
69. Richter C, Schnabel A, Csernok E et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
70. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000;93:433-9.
71. Tsurikisawa N, Taniguchi M, Saito H et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004;92: 80-7.
72. Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008;58: 308-17.
73. Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database of Syst Rev 2013;1: CD007057.
74. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it? Curr Opin Rheumatol 2003;15:237-45.
75. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997;103:38-43.